Investors Could Be Concerned With China Isotope & Radiation's (HKG:1763) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an incre
中國同輻:2023年度報告
Changes in Hong Kong stocks | China Tongshi (01763) rose more than 4%, China Nuclear Qualcomm officially has the capacity to produce and supply Nuclides such as Wancuri GMP grade N-177
The Zhitong Finance App learned that China's Tongbo (01763) rose by more than 4%. As of press release, it had risen 3.85% to HK$10.26, with a turnover of HK$1,228,800. According to the news, the China Communications Agency announced that recently, the first domestic production line with an annual output of Wanjuli grade Carrier-free Zi-177 GMP and an annual production capacity of 1,000 germanium 68Ge-68Ga generators was fully completed and put into operation, marking the actual realization of large-scale commercialization of the two GMP-grade GMP-grade GE-177 and Gallium-68 medical nuclides. The smooth commissioning of the production line will effectively mitigate domestic supply shortages of Zn-177 and Gallium-68
China Tongshi (01763.HK): CNNC Qualcomm officially has the capacity to produce and supply Nuclides such as Wancuri GMP grade -177
Gelonghui, April 22 | China Tongzhu (01763.HK) announced that recently, the first domestic-produced Wanjuli grade carrier-free -177 GMP production line, with an annual production capacity of 1,000 germanium gallium 68Ge-68Ga generators, has been fully completed and put into operation, marking the actual realization of the large-scale commercial supply of GMP-grade GMP-grade GE-177 and Gallium-68 medical nuclides.
Changes in Hong Kong stocks | China Tongshi (01763) rose more than 7% intraday to achieve full localization of carbon-14 isotopes supply
China Tongshi (01763) rose more than 7% in the intraday period. As of press release, it rose 6.49% to HK$9.85, with a turnover of HK$3.564,400.
Hong Kong Stock Concept Tracking | China's first mass production of carbon-14 isotope domestically produced nuclear drugs ushered in new opportunities (with concept stocks)
At 13:48 on April 20, after two years of core irradiation, the first carbon-14 target was successfully removed from the Qinshan Nuclear Power Heavy Water Reactor Unit of China Nuclear Power Investment Holdings under the China Nuclear Power Group. This was the first time that China mass-produced carbon-14 isotopes, solving the problem that domestic carbon-14 isotopes are dependent on imports, and fully localizing carbon-14 supply. Carbon-14 is a radioactive isotope of carbon and is widely used as a tracer. Helicobacter pylori testing is its most representative use. In addition, fields such as pharmacokinetic research and beta-ray environmental monitoring systems also require carbon-14. Previously
China Isotope & Radiation to Form JV Company
China Isotope & Radiation (HKG:1763) has entered into an agreement to form a joint venture company with CNNC Hainan Nuclear Power, a Wednesday filing on the Hong Kong bourse by the radiopharmaceutical
China Tongpu (01763) and CNNC Hainan Nuclear Power signed an investment cooperation agreement to establish a joint venture
Zhitong Finance App News, China Tongpu (01763) issued an announcement. On April 3, 2024, the company and CNNC Hainan Nuclear Power signed an investment cooperation agreement to establish a joint venture. According to the investment cooperation agreement, the registered capital of the joint venture is RMB 50 million, of which the company will invest RMB 25.5 million in monetary capital, and CNNC Hainan Nuclear Power will invest RMB 24.5 million in monetary capital. After the establishment of the joint venture, the company and CNNC Hainan Nuclear Power will hold 51% and 49% of the shares in the joint venture, respectively, and the joint venture will become a subsidiary of the company. According to the announcement, it is possible to establish a joint venture
China Tongpo (01763.HK) plans to establish a joint venture to carry out deep processing services such as preservation, preservation and sterilization of specialty agricultural products
Gelonghui, April 3, 丨 China Tongpu (01763.HK) announced that on April 3, 2024, the company and CNNC Hainan Nuclear Power entered into an investment cooperation agreement to establish a joint venture. According to the investment cooperation agreement, the registered capital of the joint venture is RMB 50 million, of which the company will invest RMB 25.5 million in monetary capital, and CNNC Hainan Nuclear Power will invest RMB 24.5 million in monetary capital. After the establishment of the joint venture, the company and CNNC Hainan Nuclear Power will hold 51% and 49% of the shares in the joint venture, respectively, and the joint venture will become a subsidiary of the company. The joint venture will use an electron accelerator
The Price Is Right For China Isotope & Radiation Corporation (HKG:1763)
With a median price-to-earnings (or "P/E") ratio of close to 9x in Hong Kong, you could be forgiven for feeling indifferent about China Isotope & Radiation Corporation's (HKG:1763) P/E ratio of 8x.
CIRC To Go Ex-Dividend On June 12th, 2024 With 0.34521 HKD Dividend Per Share
March 29th - $CIRC(01763.HK)$ is trading ex-dividend on June 12th, 2024. Shareholders of record on June 13th, 2024 will receive 0.34521 HKD dividend per share on August 6th, 2024. The ex-dividend
Changes in Hong Kong stocks | China Tongpo (01763) fell more than 6%, 23-year profit of 371 million yuan, down 5.43% year-on-year, final interest rate of 31.31 points per share
China Tongbo (01763) fell by more than 6%, down 6.43% at press time to HK$10.48, with a turnover of HK$4.53 million.
China Tongshu: Atom Hi-Tech's net profit of 256 million yuan in 2023 increased 2.77% year-on-year
China Tongshi (01763) released its 2023 annual performance report. Atomic Hi-Tech obtained total operating revenue of 1,578 billion yuan, an increase of 19.32% over the previous year; net profit attributable to shareholders of listed companies was 256 million yuan, an increase of 2.77% over the previous year; and basic earnings per share were 1.585 yuan.
China Tongfu (01763) announced 2023 results. Profit attributable to shareholders was about 371 million yuan, a year-on-year decrease of 5.43%, and final interest of 31.31 points per share
China Tongfu (01763) announced its 2023 results, with revenue of about 6.635 billion yuan, an increase of 7.8 billion yuan over the previous year...
CIRC: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
China Tongfu (01763) proposes to appoint Chen Zan as a non-executive director
China Tongfu (01763) issued an announcement. Chen Shoulei resigned as a non-executive director and deputy director of the company due to job adjustments...
China Tongshi (01763): Atom Hi-Tech's net profit of 256 million yuan in 2023 increased 2.77% year-on-year
China Tongshu (01763) released the 2023 annual performance report of the subsidiary Atomic Hi-Tech, and Atom Hi-Tech obtained total sales revenue...
CIRC: DATE OF BOARD MEETING
Hong Kong Stock Concept Tracking | The global nuclear drug market will usher in rapid growth, institutions are optimistic about the acceleration of corporate growth (with concept stocks)
As RLT therapy continues to break through, the overall market growth rate of the nuclear drug racetrack will accelerate.
Circ Re. Home Member State
No Data